FDA Approves CARBAMAZEPINE — Alembic Pharmaceuticals Inc.

Alembic Pharmaceuticals Inc. secured FDA approval on July 25, 2025, for its generic Carbamazepine oral tablet, enabling the company to expand its market presence within the established anticonvulsant segment. This regulatory milestone for ANDA219939 positions Alembic to compete alongside originator brands and drive incremental revenue growth.